Symbols / ABEO Stock $5.39 -2.36% Abeona Therapeutics Inc.

Healthcare • Biotechnology • United States • NCM
ABEO (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Vishwas Seshadri M.B.A., Ph.D.
Exch · Country NCM · United States
Market Cap 307.49M
Enterprise Value 141.06M
Income 71.18M
Sales 5.82M
FCF (ttm) -55.60M
Book/sh 2.89
Cash/sh 3.35
Employees 226
Insider 10d —
IPO Sep 19, 1980
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 5.34
Forward P/E 22.46
PEG —
P/S 52.83
P/B 1.86
P/C —
EV/EBITDA -1.62
EV/Sales 24.24
Quick Ratio 6.70
Current Ratio 6.93
Debt/Eq 15.68
LT Debt/Eq —
EPS (ttm) 1.01
EPS next Y 0.24
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-14
Earnings (prior) 2026-03-17
ROA -34.04%
ROE 70.05%
ROIC —
Gross Margin 0.00%
Oper. Margin -4.23%
Profit Margin 12.23%
Shs Outstand 57.05M
Shs Float 42.47M
Insider Own 15.68%
Instit Own 70.42%
Short Float 30.68%
Short Ratio 11.22
Short Interest 16.47M
52W High 7.54
vs 52W High -28.51%
52W Low 4.00
vs 52W Low 34.75%
Beta 1.21
Impl. Vol. 6.25%
Rel Volume 0.77
Avg Volume 1.20M
Volume 928.60K
Target (mean) $19.57
Tgt Median $20.00
Tgt Low $13.00
Tgt High $28.00
# Analysts 7
Recom None
Prev Close $5.52
Price $5.39
Change -2.36%
About

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$19.57
Mean price target
2. Current target
$5.39
Latest analyst target
3. DCF / Fair value
$-17.54
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.39
Low
$13.00
High
$28.00
Mean
$19.57

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-19 reit HC Wainwright & Co. Buy → Buy $20
2026-03-10 reit HC Wainwright & Co. Buy → Buy $20
2025-10-13 reit HC Wainwright & Co. Buy → Buy $20
2025-08-18 reit HC Wainwright & Co. Buy → Buy $20
2025-08-15 main Oppenheimer Outperform → Outperform $20
2025-07-16 reit HC Wainwright & Co. Buy → Buy $20
2025-07-14 reit HC Wainwright & Co. Buy → Buy $20
2025-05-16 main Stifel Buy → Buy $20
2025-04-30 main HC Wainwright & Co. Buy → Buy $20
2025-03-24 reit HC Wainwright & Co. Buy → Buy $15
2025-03-05 init Oppenheimer — → Outperform $16
2025-02-19 reit HC Wainwright & Co. Buy → Buy $15
2024-11-25 reit HC Wainwright & Co. Buy → Buy $15
2024-10-31 reit HC Wainwright & Co. Buy → Buy $15
2024-10-29 reit Cantor Fitzgerald Overweight → Overweight $18
2024-08-14 reit HC Wainwright & Co. Buy → Buy $15
2024-07-12 reit HC Wainwright & Co. Buy → Buy $15
2024-07-03 init HC Wainwright & Co. — → Buy $15
2024-05-30 init Stifel — → Buy $21
2024-05-16 main Cantor Fitzgerald Overweight → Overweight $21
News
RSS: Latest ABEO news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-01 GOLDAN KEITH ALAN Director — 32,751 $0.00 $0
2026-03-31 SESHADRI VISHWAS Chief Executive Officer — 29,985 $4.38 $131,481
2026-03-16 VAZZANO JOSEPH WALTER Chief Financial Officer — 785 $4.76 $3,737
2026-02-02 ALVINO MARK J. Director — 2,000 $5.09 $10,181
2026-02-02 CROMBEZ ERIC M.D. Director — 16,284 $5.09 $82,895
2026-02-02 SILVERSTEIN CHRISTINE BERNI Director — 20,070 $5.09 $102,168
2026-02-02 ALLAND LEILA Director — 18,065 $5.09 $91,962
2026-02-02 WUCHTERL DONALD A Director — 14,814 $5.09 $75,412
2026-01-26 ALVINO MARK J. Director — 37,313 $0.00 $0
2026-01-26 CROMBEZ ERIC M.D. Director — 37,313 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
5.82
0.00
-100.00%
3.50
+147.52%
1.41
Operating Revenue
3.40
0.00
-100.00%
3.50
+147.52%
1.41
Cost Of Revenue
3.42
0.00
-100.00%
1.60
+256.67%
0.45
Reconciled Cost Of Revenue
3.42
0.00
-100.00%
1.60
+256.67%
0.45
Gross Profit
2.40
0.00
-100.00%
1.90
+96.58%
0.96
Operating Expense
91.84
+43.03%
64.21
+28.18%
50.09
+8.38%
46.22
Research And Development
26.81
-21.97%
34.36
+10.51%
31.09
+7.34%
28.96
Selling General And Administration
65.03
+117.85%
29.85
+57.08%
19.00
+10.13%
17.26
General And Administrative Expense
65.03
+117.85%
29.85
+57.08%
19.00
+10.13%
17.26
Other Gand A
65.03
+117.85%
29.85
+57.08%
19.00
+10.13%
17.26
Total Expenses
95.27
+48.37%
64.21
+24.20%
51.70
+10.78%
46.67
Operating Income
-89.45
-39.30%
-64.21
-33.22%
-48.20
-6.50%
-45.26
Total Operating Income As Reported
-89.45
-39.30%
-64.21
-36.23%
-47.13
+7.42%
-50.91
EBITDA
78.59
+238.80%
-56.62
-11.96%
-50.57
-47.08%
-34.38
Normalized EBITDA
72.45
+229.68%
-55.86
-39.86%
-39.94
+0.41%
-40.11
Reconciled Depreciation
3.56
+22.57%
2.91
-9.10%
3.20
-30.13%
4.58
EBIT
75.02
+226.03%
-59.53
-10.70%
-53.77
-38.01%
-38.96
Total Unusual Items
6.14
+913.11%
-0.76
+92.90%
-10.63
-285.68%
5.72
Total Unusual Items Excluding Goodwill
6.14
+913.11%
-0.76
+92.90%
-10.63
-285.68%
5.72
Special Income Charges
—
0.00
-100.00%
1.06
+118.82%
-5.66
Other Special Charges
—
—
—
—
Impairment Of Capital Assets
—
—
0.00
-100.00%
3.15
Net Income
71.18
+211.69%
-63.73
-17.62%
-54.19
-36.51%
-39.70
Pretax Income
71.28
+211.84%
-63.73
-17.62%
-54.19
-36.51%
-39.70
Net Non Operating Interest Income Expense
1.82
+4678.95%
0.04
-97.76%
1.70
+657.05%
-0.30
Interest Expense Non Operating
3.74
-11.12%
4.21
+906.70%
0.42
-43.21%
0.74
Net Interest Income
1.82
+4678.95%
0.04
-97.76%
1.70
+657.05%
-0.30
Interest Expense
3.74
-11.12%
4.21
+906.70%
0.42
-43.21%
0.74
Interest Income Non Operating
5.56
+30.85%
4.25
+100.57%
2.12
+391.18%
0.43
Interest Income
5.56
+30.85%
4.25
+100.57%
2.12
+391.18%
0.43
Other Income Expense
158.91
+36099.32%
0.44
+105.71%
-7.69
-231.04%
5.87
Other Non Operating Income Expenses
152.78
+12695.31%
1.19
-59.43%
2.94
+1987.23%
0.14
Gain On Sale Of Security
6.14
+913.11%
-0.76
+93.54%
-11.70
-202.74%
11.38
Tax Provision
0.10
0.00
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.01
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
71.18
+211.69%
-63.73
-17.62%
-54.19
-36.51%
-39.70
Net Income From Continuing Operation Net Minority Interest
71.18
+211.69%
-63.73
-17.62%
-54.19
-36.51%
-39.70
Net Income From Continuing And Discontinued Operation
71.18
+211.69%
-63.73
-17.62%
-54.19
-36.51%
-39.70
Net Income Continuous Operations
71.18
+211.69%
-63.73
-17.62%
-54.19
-36.51%
-39.70
Normalized Income
65.05
+203.29%
-62.98
-44.59%
-43.56
+4.10%
-45.42
Net Income Common Stockholders
71.18
+211.69%
-63.73
-17.62%
-54.19
-24.63%
-43.48
Diluted EPS
1.01
+165.16%
-1.55
+38.74%
-2.53
+54.25%
-5.53
Basic EPS
1.34
+186.45%
-1.55
+38.74%
-2.53
+54.25%
-5.53
Basic Average Shares
52.95
+29.00%
41.05
+91.99%
21.38
+171.96%
7.86
Diluted Average Shares
66.14
+61.12%
41.05
+91.99%
21.38
+171.96%
7.86
Diluted NI Availto Com Stockholders
71.18
+211.69%
-63.73
-17.62%
-54.19
-24.63%
-43.48
Depreciation Amortization Depletion Income Statement
—
—
—
—
Depreciation And Amortization In Income Statement
—
—
—
—
Gain On Sale Of PPE
—
0.00
-100.00%
1.06
+142.41%
-2.51
Preferred Stock Dividends
—
—
—
3.78
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
219.57
+101.57%
108.93
+70.20%
64.00
-0.33%
64.21
Current Assets
204.91
+103.17%
100.85
+80.94%
55.74
+4.97%
53.10
Cash Cash Equivalents And Short Term Investments
191.40
+95.87%
97.72
+87.11%
52.23
+0.15%
52.15
Cash And Cash Equivalents
78.44
+235.82%
23.36
+61.38%
14.47
+1.80%
14.22
Other Short Term Investments
112.97
+51.91%
74.36
+96.97%
37.75
-0.47%
37.93
Receivables
6.71
+306.48%
1.65
-32.41%
2.44
+1200.00%
0.19
Accounts Receivable
6.15
0.00
—
0.00
Other Receivables
0.57
-65.62%
1.65
-32.41%
2.44
+1200.00%
0.19
Inventory
5.49
0.00
—
—
Raw Materials
5.49
0.00
—
—
Work In Process
0.00
0.00
—
—
Finished Goods
0.00
0.00
—
—
Prepaid Assets
—
—
—
—
Restricted Cash
0.00
-100.00%
0.34
+0.00%
0.34
+0.00%
0.34
Other Current Assets
1.29
+13.21%
1.14
+56.79%
0.73
+71.93%
0.42
Total Non Current Assets
14.66
+81.53%
8.08
-2.26%
8.27
-25.64%
11.12
Net PPE
13.88
+73.93%
7.98
-0.08%
7.99
-27.85%
11.07
Gross PPE
31.10
+35.45%
22.96
+9.45%
20.98
-8.59%
22.95
Accumulated Depreciation
-17.22
-14.94%
-14.98
-15.31%
-12.99
-9.36%
-11.88
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
1.96
+76.28%
1.11
+12.88%
0.99
-28.50%
1.38
Construction In Progress
0.00
-100.00%
0.62
0.00
0.00
Other Properties
14.02
+12.91%
12.42
+9.04%
11.39
-12.16%
12.97
Leases
15.12
+71.68%
8.80
+2.35%
8.60
-0.02%
8.61
Goodwill And Other Intangible Assets
—
—
—
0.00
Goodwill
—
—
—
—
Other Intangible Assets
—
—
—
—
Other Non Current Assets
0.78
+713.54%
0.10
-65.34%
0.28
+544.19%
0.04
Total Liabilities Net Minority Interest
60.35
-7.00%
64.90
+31.97%
49.18
+31.30%
37.45
Current Liabilities
29.57
+78.27%
16.59
+23.58%
13.42
+72.54%
7.78
Payables And Accrued Expenses
10.85
+101.52%
5.38
-38.39%
8.73
+172.20%
3.21
Payables
8.02
+132.93%
3.44
-46.55%
6.44
+255.49%
1.81
Accounts Payable
7.89
+129.26%
3.44
+85.20%
1.86
+2.60%
1.81
Other Payable
—
—
4.58
—
Current Accrued Expenses
2.83
+45.85%
1.94
-15.50%
2.30
+64.31%
1.40
Pensionand Other Post Retirement Benefit Plans Current
5.64
+28.32%
4.39
+19.09%
3.69
+42.23%
2.59
Total Tax Payable
0.13
0.00
—
—
Current Debt And Capital Lease Obligation
13.09
+93.90%
6.75
+576.25%
1.00
-43.71%
1.77
Current Debt
12.22
+106.24%
5.93
—
—
Other Current Borrowings
12.22
+106.24%
5.93
—
—
Current Capital Lease Obligation
0.86
+4.98%
0.82
-17.54%
1.00
-43.71%
1.77
Current Deferred Liabilities
—
—
—
—
Current Deferred Revenue
—
—
—
—
Other Current Liabilities
0.00
-96.88%
0.06
+6300.00%
0.00
-99.51%
0.20
Total Non Current Liabilities Net Minority Interest
30.78
-36.28%
48.31
+35.13%
35.75
+20.49%
29.67
Long Term Debt And Capital Lease Obligation
11.88
-27.10%
16.30
+270.26%
4.40
-24.80%
5.85
Long Term Debt
7.81
-40.07%
13.04
—
—
Long Term Capital Lease Obligation
4.07
+24.74%
3.26
-25.90%
4.40
-24.80%
5.85
Tradeand Other Payables Non Current
—
—
0.00
-100.00%
4.16
Other Non Current Liabilities
—
—
—
—
Stockholders Equity
159.22
+261.60%
44.03
+196.99%
14.83
-44.60%
26.76
Common Stock Equity
159.22
+261.60%
44.03
+196.99%
14.83
-44.60%
26.76
Capital Stock
0.55
+20.35%
0.46
+72.45%
0.27
+49.72%
0.18
Common Stock
0.55
+20.35%
0.46
+72.45%
0.27
+49.72%
0.18
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
55.04
+20.59%
45.64
+72.09%
26.52
+49.69%
17.72
Ordinary Shares Number
55.04
+20.59%
45.64
+72.09%
26.52
+49.69%
17.72
Additional Paid In Capital
900.60
+5.11%
856.82
+12.13%
764.15
+5.83%
722.05
Retained Earnings
-742.08
+8.75%
-813.26
-8.50%
-749.52
-7.79%
-695.34
Gains Losses Not Affecting Retained Earnings
0.14
+1625.00%
0.01
+112.12%
-0.07
+48.84%
-0.13
Other Equity Adjustments
0.14
+1625.00%
0.01
+112.12%
-0.07
+48.84%
-0.13
Total Equity Gross Minority Interest
159.22
+261.60%
44.03
+196.99%
14.83
-44.60%
26.76
Total Capitalization
167.03
+192.68%
57.07
+284.92%
14.83
-44.60%
26.76
Working Capital
175.34
+108.07%
84.27
+99.14%
42.31
-6.63%
45.32
Invested Capital
179.25
+184.55%
62.99
+324.89%
14.83
-44.60%
26.76
Total Debt
24.97
+8.33%
23.05
+326.81%
5.40
-29.20%
7.63
Capital Lease Obligations
4.93
+20.76%
4.08
-24.35%
5.40
-29.20%
7.63
Net Tangible Assets
159.22
+261.60%
44.03
+196.99%
14.83
-44.60%
26.76
Tangible Book Value
159.22
+261.60%
44.03
+196.99%
14.83
-44.60%
26.76
Derivative Product Liabilities
18.90
-40.96%
32.01
+2.11%
31.35
+59.50%
19.66
Preferred Shares Number
29.38
+0.00%
29.38
+0.00%
29.38
+0.00%
29.38
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-76.33
-36.26%
-56.02
-51.36%
-37.01
+14.89%
-43.48
Cash Flow From Continuing Operating Activities
-76.33
-36.26%
-56.02
-51.36%
-37.01
+14.89%
-43.48
Net Income From Continuing Operations
71.18
+211.69%
-63.73
-17.62%
-54.19
-36.51%
-39.70
Depreciation Amortization Depletion
3.56
+22.57%
2.91
-9.10%
3.20
-30.13%
4.58
Depreciation
3.56
+22.57%
2.91
-9.10%
3.20
-30.13%
4.58
Depreciation And Amortization
3.56
+22.57%
2.91
-9.10%
3.20
-30.13%
4.58
Other Non Cash Items
2.04
+12.51%
1.81
+459.88%
0.32
-8.99%
0.36
Stock Based Compensation
10.78
+62.63%
6.63
+39.01%
4.77
+56.28%
3.05
Asset Impairment Charge
—
—
0.00
-100.00%
3.15
Operating Gains Losses
-158.50
-21149.80%
0.75
-92.95%
10.68
+218.29%
-9.03
Gain Loss On Investment Securities
-6.14
-913.11%
0.76
-93.54%
11.70
+202.74%
-11.38
Gain Loss On Sale Of PPE
0.00
+100.00%
-0.00
+99.80%
-1.02
-143.19%
2.36
Change In Working Capital
-5.39
-22.91%
-4.38
-145.13%
-1.79
+69.65%
-5.89
Change In Receivables
-5.06
-739.27%
0.79
+138.80%
-2.04
-172.58%
2.81
Changes In Account Receivables
-6.15
0.00
0.00
-100.00%
3.00
Change In Inventory
-5.49
0.00
—
—
Change In Prepaid Assets
-0.15
+73.23%
-0.56
-263.87%
-0.15
-107.94%
1.95
Change In Payables And Accrued Expense
6.67
+290.84%
-3.49
-271.14%
2.04
+122.41%
-9.11
Change In Payable
6.67
+290.84%
-3.49
-271.14%
2.04
+122.41%
-9.11
Change In Account Payable
6.54
+287.23%
-3.49
-271.14%
2.04
+122.41%
-9.11
Change In Other Working Capital
—
—
—
-0.29
Change In Other Current Assets
-0.69
-478.45%
0.18
+177.35%
-0.23
-287.20%
0.12
Change In Other Current Liabilities
-0.66
+49.11%
-1.30
+7.15%
-1.40
+16.43%
-1.67
Investing Cash Flow
105.03
+367.66%
-39.24
-18965.38%
0.21
+100.87%
-23.96
Cash Flow From Continuing Investing Activities
105.03
+367.66%
-39.24
-18965.38%
0.21
+100.87%
-23.96
Net PPE Purchase And Sale
0.00
-100.00%
0.02
-91.18%
0.20
-88.24%
1.73
Sale Of PPE
0.00
-100.00%
0.02
-91.18%
0.20
-88.24%
1.73
Capital Expenditure
-7.97
-226.04%
-2.45
-638.97%
-0.33
-154.62%
-0.13
Capital Expenditure Reported
-7.97
-226.04%
-2.45
-638.97%
-0.33
-154.62%
-0.13
Net Investment Purchase And Sale
-39.36
-6.93%
-36.81
-11088.66%
0.34
+101.31%
-25.57
Purchase Of Investment
-206.63
-31.61%
-157.01
-204.07%
-51.64
+33.98%
-78.21
Sale Of Investment
167.27
+39.16%
120.20
+131.28%
51.97
-1.28%
52.64
Net Other Investing Changes
152.37
—
—
—
Financing Cash Flow
26.04
-74.99%
104.14
+181.02%
37.06
-14.17%
43.17
Cash Flow From Continuing Financing Activities
26.04
-74.99%
104.14
+181.02%
37.06
-14.17%
43.17
Net Issuance Payments Of Debt
0.00
-100.00%
20.00
0.00
—
Issuance Of Debt
0.00
-100.00%
20.00
0.00
—
Long Term Debt Issuance
0.00
-100.00%
20.00
0.00
—
Net Long Term Debt Issuance
0.00
-100.00%
20.00
0.00
—
Net Common Stock Issuance
17.30
-79.80%
85.63
+129.02%
37.39
-20.38%
46.96
Repurchase Of Capital Stock
—
—
0.00
+100.00%
-26.25
Proceeds From Stock Option Exercised
8.78
0.00
+100.00%
-0.18
-3540.00%
-0.01
Net Other Financing Charges
-0.04
+97.52%
-1.49
-348.49%
-0.33
—
Changes In Cash
54.74
+516.19%
8.88
+3370.31%
0.26
+101.05%
-24.27
Beginning Cash Position
23.70
+59.98%
14.81
+1.76%
14.55
-62.52%
38.83
End Cash Position
78.44
+231.03%
23.70
+59.98%
14.81
+1.76%
14.55
Free Cash Flow
-84.30
-44.20%
-58.46
-56.56%
-37.34
+14.38%
-43.61
Interest Paid Supplemental Data
2.59
-3.03%
2.67
0.00
—
Income Tax Paid Supplemental Data
0.00
-100.00%
0.01
-50.00%
0.01
—
Change In Income Tax Payable
0.13
0.00
—
—
Change In Tax Payable
0.13
0.00
—
—
Common Stock Issuance
17.30
-79.80%
85.63
+129.02%
37.39
-20.38%
46.96
Issuance Of Capital Stock
17.30
-79.80%
85.63
+129.02%
37.39
-46.15%
69.43
Net Preferred Stock Issuance
—
—
0.00
+100.00%
-3.78
Preferred Stock Issuance
—
—
0.00
-100.00%
22.47
Preferred Stock Payments
—
—
0.00
+100.00%
-26.25
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category